A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Extensive Stage Small Cell Lung Cancer

In brief

The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.

Key facts

Study ID

NCT06016270

Run by

STCube, Inc.

People needed

10

Starts

2024-02-13

Expected to finish

2025-08-25

Last updated by the study team

2025-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to understand and sign an informed consent form
• Male or female ≥ 18 years of age
• Histologically or cytologically confirmed SCLC
• R/R ES-SCLC on or after platinum-based chemotherapy for SCLC with documented disease progression
• At least 1 measurable lesion as defined by RECIST 1.1
• Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 or 1
• Life expectancy of at least 3 months
• Adequate organ function as described in the protocol
• For female or male patients with reproductive potential: Agree to use contraception throughout the study and at least 5 months after the last dose.

You may not qualify if…

• Known active leptomeningeal disease (carcinomatous meningitis)
• Known active and uncontrolled central nervous system (CNS) metastases
• Treatment with immunotherapy, chemotherapy, targeted small molecule therapy, or any other investigational agent < 14 days prior to initiation of study treatment
• Treatment with radiation therapy < 14 days prior to initiation of study treatment
• Major surgery < 21 days prior to initiation of study treatment
• Received live vaccine < 30 days prior to initiation of study treatment, including intranasal influenza vaccine
• History of another primary malignancy with protocol-defined exceptions
• Active or history of autoimmune disease requiring systemic treatment
• Receiving high doses of steroids or other immunosuppressive medications
• Active hepatitis B or C infection
• Active or history of non-infectious pneumonitis requiring treatment with steroids
• Active uncontrolled viral, fungal, or bacterial infection including tuberculosis
• Pregnant or breastfeeding female patients
• History of severe hypersensitivity reaction to a monoclonal antibody treatment
• History of severe hypersensitivity reaction or ≥ Grade 3 adverse event (AE) to paclitaxel treatment
• History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms within 6 months prior to screening
• QT Corrected for Fridericia's method (QTcF) > 470 ms at screening
• Lack of resolution of any toxicity to max Grade 1 (except alopecia)
• Active or history of any condition, therapy, or lab abnormality that may interfere with the patient participation for the full duration of the study
• Known psychiatric or substance use disorder
• Positive Coronavirus disease 2019 (COVID-19) test at screening

Where it is running

• Tisch Cancer Institute at Mount Sinai — New York, New York, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Korea University Anam Hospital — Seoul, South Korea
• Seoul National University Hospital — Seoul, South Korea
• Asan Medical Center — Seoul, South Korea
• Samsung Medical Center — Seoul, South Korea
• Seoul National University Bundang Hospital — Seoul, South Korea
• The Catholic University of Korea St. Vincent's Hospital — Suwon, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.